DNB Asset Management AS Acquires 977 Shares of United Therapeutics Corporation $UTHR

DNB Asset Management AS increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 13.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,483 shares of the biotechnology company’s stock after buying an additional 977 shares during the period. DNB Asset Management AS’s holdings in United Therapeutics were worth $4,133,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC bought a new stake in shares of United Therapeutics during the second quarter worth approximately $277,000. Cerity Partners LLC raised its stake in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia increased its stake in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $586.75, for a total transaction of $4,870,025.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $26,504,671. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,708,543.56. The trade was a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 550,413 shares of company stock valued at $305,867,937. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ:UTHR opened at $566.80 on Wednesday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company’s fifty day simple moving average is $561.48 and its 200 day simple moving average is $509.54. The firm has a market cap of $24.06 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the business earned $6.63 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on UTHR shares. Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.